Process development of a SARS-CoV-2 nanoparticle vaccine.

ABSTRACT: One of the outcomes from the global COVID-19 pandemic caused by SARS-CoV-2 has been an acceleration of development timelines to provide treatments in a timely manner. For example, it has recently been demonstrated that the development of monoclonal antibody therapeutics from vector construction to IND submission can be achieved in five to six months rather than the traditional ten-to-twelve-month timeline using CHO cells [1], [2]. This timeline is predicated on leveraging existing, robust platforms for upstream and downstream processes, analytical methods, and formulation. These platforms also reduce; the requirement for ancillary studies such as cell line stability, or long-term product stability studies. Timeline duration was further reduced by employing a transient cell line for early m

SUBMITTER: Martinez-Cano D 

PROVIDER: S-EPMC10019920 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature